Comparison of the effects of deferasirox film-coated tablets (Jadenu®) and deferasirox dispersible tablets (Exjade®) in patients with beta thalassemia major: a preliminary report of the effects on the satisfaction, convenience, cardiac/liver MRI T2*, serum ferritin level, and biochemical profiles
BackgroundDeferasirox (DFX) is a once-daily oral iron chelator with proven dose-dependent efficacy in patients with thalassemia major (TM). The reason for switching from DFX dispersible tablets (Exjade®) to DFX film-coated tablets (Jadenu®) was intolerance. Many patients also reported that deferasir...
Saved in:
Main Authors: | Mahya Mobinikhaledi (Author), Vahid Falahati (Author), Amin Tajerian (Author), Amir Almasi Hashiani (Author), Kazem Ghaffari (Author), Ali Ghasemi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Switching from Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets: Is There an Effect on Ferritin Levels in Children and Adolescents with Transfusion-Dependent Anemia?
by: Esra Arslantaş, et al.
Published: (2024) -
Deferasirox adherence in patients with thalassemia: Exploring the association with patient knowledge and ferritin levels
by: Reem Ali Shaker, et al.
Published: (2024) -
Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
by: Mohammadreza Rafati, et al.
Published: (2022) -
Pengaruh Deferasirox Terhadap Kadar T4 dan TSH Pada B-Thalassemia Mayor dengan Kadar Ferritin Tinggi
by: Dewi Ratih P, et al.
Published: (2016) -
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015)